PHARMING GROUP NV (PHGN.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:PHGN - NL0010391025 - Common Stock
PHGN.DE Key Statistics, Chart & Performance
The current stock price of PHGN.DE is 1.442 EUR.
PHGN.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.44 | 48.25B | ||
| 1AE.DE | ARGENX SE | 73.33 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.03B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.80B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.78B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.80B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.79B | ||
| 5CV.DE | CUREVAC NV | 7.64 | 997.95M | ||
| NANO.PA | NANOBIOTIX | N/A | 882.34M | ||
| PHIL.MI | PHILOGEN SPA | 20.18 | 672.52M | ||
| 6IV.DE | INVENTIVA SA | N/A | 678.11M | ||
| IVA.PA | INVENTIVA SA | N/A | 668.56M |
Related stock screener links
About PHGN.DE
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 404
Phone: 31715247400
PHARMING GROUP NV / PHGN.DE FAQ
What does PHGN do?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
What is the stock price of PHARMING GROUP NV today?
The current stock price of PHGN.DE is 1.442 EUR. The price increased by 7.05% in the last trading session.
Does PHGN stock pay dividends?
PHGN.DE does not pay a dividend.
How is the ChartMill rating for PHARMING GROUP NV?
PHGN.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about PHARMING GROUP NV (PHGN.DE) stock?
14 analysts have analysed PHGN.DE and the average price target is 2.01 EUR. This implies a price increase of 39.35% is expected in the next year compared to the current price of 1.442.
PHGN.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PHGN.DE.
PHGN.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE. PHGN.DE has only an average score on both its financial health and profitability.
PHGN.DE Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.03% | ||
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| Debt/Equity | 0.46 |
PHGN.DE Forecast & Estimates
14 analysts have analysed PHGN.DE and the average price target is 2.01 EUR. This implies a price increase of 39.35% is expected in the next year compared to the current price of 1.442.
For the next year, analysts expect an EPS growth of 287.06% and a revenue growth 25.91% for PHGN.DE